Ceftazidime-Avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: A systematic review and meta-analysis

Introduction: Ceftazidime-avibactam (CAZ-AVI) is a combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam that is approved for the treatment of pediatric (≥ 3 months) and adult patients with complicated infections including hospital-...

Descripción completa

Detalles Bibliográficos
Autores: Shields, Ryan K., Horcajada Gallego, Juan Pablo, Kamat, Shweta, Irani, Paurus M., Tawadrous, Margaret, Welte, Tobias
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/60757
Acceso en línea:http://hdl.handle.net/10230/60757
http://dx.doi.org/10.1007/s40121-024-00999-y
Access Level:acceso abierto
Palabra clave:Bacteremia
Ceftazidime-avibactam
Clinical cure
Hospital-associated pneumonia
Mortality
Nosocomial pneumonia
Ventilator-associated pneumonia
id ES_1ea00a9d24f0a9b696c5bc2a3d48f09b
oai_identifier_str oai:repositori.upf.edu:10230/60757
network_acronym_str ES
network_name_str España
repository_id_str
spelling Ceftazidime-Avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: A systematic review and meta-analysisShields, Ryan K.Horcajada Gallego, Juan PabloKamat, ShwetaIrani, Paurus M.Tawadrous, MargaretWelte, TobiasBacteremiaCeftazidime-avibactamClinical cureHospital-associated pneumoniaMortalityNosocomial pneumoniaVentilator-associated pneumoniaIntroduction: Ceftazidime-avibactam (CAZ-AVI) is a combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam that is approved for the treatment of pediatric (≥ 3 months) and adult patients with complicated infections including hospital-acquired and ventilator-associated pneumonia (HAP/VAP), and bacteremia. This systematic literature review and meta-analysis (PROSPERO registration: CRD42022362856) aimed to provide a quantitative and qualitative synthesis to evaluate the effectiveness of CAZ-AVI in treating adult patients with bacteremia or nosocomial pneumonia caused by carbapenem-resistant Enterobacterales (non metallo-β-lactamase-producing strains) and multi-drug resistant (MDR) Pseudomonas aeruginosa infections. Methods: The databases included in the search, until November 7, 2022, were Embase and PubMed. A total of 24 studies (retrospective: 22, prospective: 2) with separate outcomes for patients with bacteremia or pneumonia were included. Results: The outcomes assessed were all-cause mortality, clinical cure, and microbiological cure. Qualitative (24 studies) and quantitative (8/24 studies) syntheses were performed. The quality of the studies was assessed using the MINORS checklist and the overall risk of bias was moderate to high. Conclusions: In studies included in the meta-analysis, lower all-cause mortality for patients with bacteremia (OR = 0.30, 95% CI 0.19-0.46) and improved rates of clinical cure for patients with bacteremia (OR = 4.90, 95% CI 2.60-9.23) and nosocomial pneumonia (OR = 3.20, 95% CI 1.55-6.60) was observed in the CAZ-AVI group compared with the comparator group. Data provided here may be considered while using CAZ-AVI for the treatment of patients with difficult-to-treat infections. Systematic review registration: PROSPERO CRD42022362856.Springer202420242024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/60757http://dx.doi.org/10.1007/s40121-024-00999-yreponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésInfect Dis Ther. 2024 Jul;13(7):1639-64© Pfzer Inc 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.http://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/607572026-06-12T07:21:37Z
dc.title.none.fl_str_mv Ceftazidime-Avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: A systematic review and meta-analysis
title Ceftazidime-Avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: A systematic review and meta-analysis
spellingShingle Ceftazidime-Avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: A systematic review and meta-analysis
Shields, Ryan K.
Bacteremia
Ceftazidime-avibactam
Clinical cure
Hospital-associated pneumonia
Mortality
Nosocomial pneumonia
Ventilator-associated pneumonia
title_short Ceftazidime-Avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: A systematic review and meta-analysis
title_full Ceftazidime-Avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: A systematic review and meta-analysis
title_fullStr Ceftazidime-Avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: A systematic review and meta-analysis
title_full_unstemmed Ceftazidime-Avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: A systematic review and meta-analysis
title_sort Ceftazidime-Avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: A systematic review and meta-analysis
dc.creator.none.fl_str_mv Shields, Ryan K.
Horcajada Gallego, Juan Pablo
Kamat, Shweta
Irani, Paurus M.
Tawadrous, Margaret
Welte, Tobias
author Shields, Ryan K.
author_facet Shields, Ryan K.
Horcajada Gallego, Juan Pablo
Kamat, Shweta
Irani, Paurus M.
Tawadrous, Margaret
Welte, Tobias
author_role author
author2 Horcajada Gallego, Juan Pablo
Kamat, Shweta
Irani, Paurus M.
Tawadrous, Margaret
Welte, Tobias
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Bacteremia
Ceftazidime-avibactam
Clinical cure
Hospital-associated pneumonia
Mortality
Nosocomial pneumonia
Ventilator-associated pneumonia
topic Bacteremia
Ceftazidime-avibactam
Clinical cure
Hospital-associated pneumonia
Mortality
Nosocomial pneumonia
Ventilator-associated pneumonia
description Introduction: Ceftazidime-avibactam (CAZ-AVI) is a combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam that is approved for the treatment of pediatric (≥ 3 months) and adult patients with complicated infections including hospital-acquired and ventilator-associated pneumonia (HAP/VAP), and bacteremia. This systematic literature review and meta-analysis (PROSPERO registration: CRD42022362856) aimed to provide a quantitative and qualitative synthesis to evaluate the effectiveness of CAZ-AVI in treating adult patients with bacteremia or nosocomial pneumonia caused by carbapenem-resistant Enterobacterales (non metallo-β-lactamase-producing strains) and multi-drug resistant (MDR) Pseudomonas aeruginosa infections. Methods: The databases included in the search, until November 7, 2022, were Embase and PubMed. A total of 24 studies (retrospective: 22, prospective: 2) with separate outcomes for patients with bacteremia or pneumonia were included. Results: The outcomes assessed were all-cause mortality, clinical cure, and microbiological cure. Qualitative (24 studies) and quantitative (8/24 studies) syntheses were performed. The quality of the studies was assessed using the MINORS checklist and the overall risk of bias was moderate to high. Conclusions: In studies included in the meta-analysis, lower all-cause mortality for patients with bacteremia (OR = 0.30, 95% CI 0.19-0.46) and improved rates of clinical cure for patients with bacteremia (OR = 4.90, 95% CI 2.60-9.23) and nosocomial pneumonia (OR = 3.20, 95% CI 1.55-6.60) was observed in the CAZ-AVI group compared with the comparator group. Data provided here may be considered while using CAZ-AVI for the treatment of patients with difficult-to-treat infections. Systematic review registration: PROSPERO CRD42022362856.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/60757
http://dx.doi.org/10.1007/s40121-024-00999-y
url http://hdl.handle.net/10230/60757
http://dx.doi.org/10.1007/s40121-024-00999-y
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Infect Dis Ther. 2024 Jul;13(7):1639-64
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404352183009280
score 15.811543

Similares en LA Referencia